Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants

2 Mar 2023

Abstract excerpt

Rapid emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted an urgent need for the development of broadly applicable and potently neutralizing antibody platform against the SARS-CoV-2, which can be used for combatting the coronavirus disease 2019 (COVID-19). In this study, based on a noncompeting pair of phage display-derived human monoclonal antibodies (mAbs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36870394
DOI: 10.1016/j.antiviral.2023.105576

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variantsPMID 36870394Read ↗

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity Read ↗

Fully human single-domain antibodies against SARS-CoV-2Semantic proximity Read ↗

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617Semantic proximity Read ↗

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617Semantic proximity Read ↗

Dual Epitope Engagement Enables Broad-Spectrum Neutralization of SARS-CoV-2 Variants by Bispecific Antibody 9A6-6C3Semantic proximity Read ↗

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read ↗

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernSemantic proximity Read ↗

Development of Fully Human, Bispecific Antibodies that Effectively Block Omicron Variant Pseudovirus InfectionsSemantic proximity Read ↗

A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.Semantic proximity Read ↗

Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modalitySemantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.